NTLA (Intellia Therapeutics, Inc.) Stock Financials & Earnings

NTLAIntellia Therapeutics, Inc.

Mkt Cap$2B

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Revenue (TTM)$68M

Net Income (TTM)-$413M

EPS (TTM)-$3.83

Free Cash Flow (TTM)-$396M

Gross Margin-25.6%

Op. Margin-651.7%

Net Margin-609.9%

FCF Margin-585.0%

P/S Ratio (TTM)24.2x

P/E Ratio (TTM)—

YoY Rev Growth+16.9%

Employees—

Earnings Reports

Revenue & Profitability

Quarter	Revenue	Gross Profit	Op. Income
Q1 23	$13M	-$85M	-$112M
Q2 23	$14M	-$102M	-$132M
Q3 23	$12M	$10M	-$131M
Q4 23	-$2M	-$4M	-$140M
Q1 24	$29M	$26M	-$114M
Q2 24	$7M	$4M	-$139M
Q3 24	$9M	$9M	-$145M
Q4 24	$13M	$13M	-$136M
Q1 25	$17M	$17M	-$121M
Q2 25	$14M	$14M	-$110M
Q3 25	$14M	-$65M	-$111M
Q4 25	$23M	$17M	-$99M

Valuation

Operating Cash Flow

Capital Expenditures

CapEx

OpEx vs Revenue Growth (YoY)

Stock-Based Compensation

OpEx Breakdown

Quarter	R&D	G&A	S&M
Q1 23	$97M	$27M	—
Q2 23	$115M	$31M	—
Q3 23	$114M	$29M	—
Q4 23	$109M	$29M	—
Q1 24	$109M	$31M	—
Q2 24	$112M	$32M	—
Q3 24	$123M	$31M	—
Q4 24	$117M	$32M	—
Q1 25	$108M	$29M	—
Q2 25	$97M	$27M	—
Q3 25	$95M	$31M	$16M
Q4 25	$89M	$33M	—

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 23	$294M	$639M	$934M
Q2 23	$172M	$736M	$908M
Q3 23	$168M	$687M	$855M
Q4 23	$227M	$685M	$912M
Q1 24	$172M	$619M	$791M
Q2 24	$131M	$560M	$691M
Q3 24	$120M	$538M	$658M
Q4 24	$189M	$412M	$602M
Q1 25	$127M	$377M	$504M
Q2 25	$156M	$303M	$460M
Q3 25	$193M	$318M	$511M
Q4 25	$155M	$294M	$450M

Shares Outstanding

Revenue Per Employee

Revenue / Employee